Showing 1 - 10 of 22
We examine cost-plus lagged-price reimbursement contracts, focusing on Medicare Part B's payment for physician-administered drugs. Our theoretical model shows that lagged-price reimbursement can raise launch prices but lower prices in later periods. While previous research showed Part B...
Persistent link: https://www.econbiz.de/10014436965
Persistent link: https://www.econbiz.de/10009627373
Persistent link: https://www.econbiz.de/10010350845
Fragmented healthcare received from many different physicians results in higher costs and lower quality, but does it contribute to dangerous opioid prescribing? The effect is theoretically ambiguous because fragmentation can trigger costly coordination failures but also permits greater...
Persistent link: https://www.econbiz.de/10013191086
I use the Medicare Part D prescription drug insurance market to examine the dynamics of firm interaction with consumers on an insurance exchange. Enrollment data show that consumers face switching frictions leading to inertia in plan choice, and a regression discontinuity design indicates...
Persistent link: https://www.econbiz.de/10012460300
I use the Medicare Part D prescription drug insurance market to examine the dynamics of firm interaction with consumers on an insurance exchange. Enrollment data show that consumers face switching frictions leading to inertia in plan choice, and a regression discontinuity design indicates...
Persistent link: https://www.econbiz.de/10013100991
Persistent link: https://www.econbiz.de/10014514650
Persistent link: https://www.econbiz.de/10010510664
Persistent link: https://www.econbiz.de/10011428564
Effectively designed market mechanisms may reduce growth in health care spending. In this paper, we study the impact of privatizing the delivery of Medicaid drug benefits on drug spending. Exploiting granular data that allow us to examine drug utilization, we find that drug spending would fall...
Persistent link: https://www.econbiz.de/10012945134